Dainippon and Takeda Sign an Agreement Regarding a New Anti-Diabetic Agent
OSAKA,JAPAN --- Dainippon Pharmaceutical Co., Ltd. (gDainipponh, President: Kenjiro Miyatake) and Takeda Chemical Industries, Ltd. (gTakedah, President: Kunio Takeda) jointly announced today that they signed an agreement that Takeda receives the development and marketing rights of Dainipponf s new anti-diabetic agent, AJ-9677 (Takedafs development code: TAK-677), in the world except Japan, China, Taiwan and South Korea.
AJ-9677, created by Dainippon, is a β3-adrenaline receptor agonist which improves both lipid and glycemic metabolism by reducing insulin resistance and is accordingly expected to be a new class of anti-diabetic agent for type 2 diabetes. Moreover, since this compound has the function of promoting energy consumption, it has a potential to be developed as an anti-obesity drug.
Dainippon believes that AJ-9677, which is now under phase I clinical studies in Japan, is a strategically important product for their pharmaceutical Business.
Takeda believes that the compound will be beneficial to expand their anti-diabetic product line for their global business activities, and plans to initiate phase I clinical studies for TAK-677 in the United States soon.
Dainippon and Takeda will cooperate closely to promote the development of AJ-9677 (TAK-677) in the United States, Europe and Japan.
This alliance was announced when the preliminary agreement was signed on September 29, 1999.